Dr. David Zaccardelli is a biopharmaceutical executive with extensive leadership experience building and scaling life sciences companies. He served as President, Chief Executive Officer, and board member of Verona Pharma from 2020 until its $10 billion acquisition by Merck in 2025, leading the company through pivotal Phase 3 trials, FDA approval, and the launch of Ohtuvayre® for chronic obstructive pulmonary disease. Previously, he was President and Chief Executive Officer of Dova Pharmaceuticals, acquired by Swedish Orphan Biovitrum for up to $915 million, and held senior leadership roles at Cempra and United Therapeutics. He currently serves as Chair of the Board of Directors for SAB BIO and Founder and Managing Member of Bull City Select Investments, LLC. Dr. Zaccardelli received a PharmD from the University of Michigan and completed a fellowship in clinical research and drug development at the University of North Carolina.
